With certainty we can look back on 2015 and 2016 as the years that Olympus made an official expansion from leadership primarily in capital equipment to also being an established leader in EndoTherapy devices, said Kurt Heine, Group Vice President, Endoscopy Division at Olympus America Inc. The company has been on the forefront of EndoTherapy innovations for years, which have furthered the healthcare industrys progress toward Triple Aim goals of the Affordable Care Act, of improving patient outcomes, reducing costs and improving patient satisfaction.
High-volume procedures requiring the use of GI endoscopy devices such as colonoscopy, esophagogastroduodenoscopy (EGD) and biopsy will be primary drivers of the U.S. GI endoscopy device market, which was valued at approximately $2.3 billion in 2014 and forecasted for moderate growth, according to the Millennium Research Group.
“With the Affordable Care Act financially incentivizing healthcare providers for improved outcomes, leading vendors in this space have had to offer more than just capital equipment to address more of a service line. Olympus has expanded their offering to a large line of instruments, consumables, and leading-edge ablation technologies. All of this has allowed providers to simplify their purchasing processes through standardization and to take advantage of consumable financing
